Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis

Gastroenterology

Volumn 109, Issue 2, 1995, Pages 531-539

  Violi, Francesco ^a   Ferro, Domenico ^a   Basili, Stefania ^a   Saliola, Mirella ^a   Quintarelli, Claudio ^a   Alessandri, Cesare ^a   Cordova, Corrado ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 2 ANTIPLASMIN; ANTIBIOTIC AGENT; BACITRACIN; COLISTIN; ETACRYNIC ACID; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; FUROSEMIDE; LACTULOSE; NEOMYCIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; SPIRONOLACTONE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTOXEMIA; FEMALE; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERCOAGULABILITY; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0029155948     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/0016-5085(95)90342-9     Document Type: Article

References (48)

1. Hemostatic abnormalities in liver disease
2. Clotting abnormalities in chronic liver disease
3. Prevalence of hyperfibrinolysis in patients with liver cirrhosis
4. Disseminated intravascular coagulation in cirrhosis
5. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for plasminogen activator inhibitor
6. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis
7. In vivo metabolism of human tissue type plasminogen activator
8. 2-plasmin inhibitor mechanism in patients with liver cirrhosis
9. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis
10. Fibrinogen survival in cirrhosis: improvement by “low dose” heparin
11. Improvement of some blood coagulation factors in cirrhotic patients treated with low doses of heparin
12. Exchange between intravascularly and extravascularly injected radioiodinated fibrinogen and its in vivo derivatives
13. Significance of plasma fibrinopeptide A and high molecular weight fibrinogen in patients with liver cirrhosis
14. Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases.
15. Disseminated intravascular coagulation in liver cirrhosis
16. Studies of the prothrombin activation pathway utilizing radioimmunoassay for the F2/F1+2 fragment and thrombin-antithrombin complex
17. Multicentric evaluation of a new assay for prothrombin fragment F1+2 determination
18. Systemic clotting activation in liver cirrhosis patients: the role of endotoxemia
19. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis
20. Direct induction of tissue factor synthesis by endotoxin in human macrophages from diverse anatomical sites
21. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro
22. Transection of oesophagus for bleeding oesophagus varices
23. Prekallikrein and factor VII as prognostic indexes of liver failure
24. Determination of human prothrombin activation fragment F1+2 in plasma with an antibody against a synthetic peptide
25. Measurement of plasminogen activator inhibitor-1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay
26. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess
27. Quantitative endotoxin determination in blood with a chromogenic substrate
28. Chromogenic endotoxin assay in plasma selection of plasma pretreatment and production of standard curves
29. Bleeding in cirrhotic patients: a precipitating factor due to intravascular coagulation or to hepatic failure?
30. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis
31. Clinical significance of accelerated fibrinolysis in liver cirrhosis
32. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage
33. Markers of coagulant imbalance in patients with localized melanomas and autoimmune disorders
34. Association of abnormal fibrin polymerization with severe liver disease
35. The pathophysiology of the prothrombotic state in humans: insights gained from studies using markers of hemostatic system activation
36. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen
37. Tissue plasminogen activator and plasminogen activator inhibitor in patients with liver cirrhosis
38. Cultured human endothelial cells generate tissue factor in response to endotoxins
39. Detection of circulating tumor necrosis factor after endotoxin administration
40. Activation of coagulation after administration of tumor necrosis factor to normal subjects
41. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways
42. ON THE ABSORPTION OF BACTERIAL ENDOTOXIN FROM THE GASTRO-INTESTINAL TRACT OF THE NORMAL AND SHOCKED ANIMAL
43. Hepatic clearance of endotoxins: differences in arterial and portal perfusion
44. Endotoxins and the pathogenesis of hepatic and gastrointestinal diseases
45. The role of endotoxin in liver injury
46. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay
47. Endotoxemia in liver disease—time for re-appraisal?